You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Single-session bronchial thermoplasty for severe asthmatics guided by HXe MRI

    SBC: XEMED LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Roughly one million Americans with inadequately controlled severe persistent asthma have a particularly high risk of exacerbations hospitalizations and death and account for a per patient health care burden exceeding $ annually Bronchial thermoplasty BT applies radiofrequency heating to airway smooth muscle reducing its thickness and hyper reactivity This novel mi ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Safe and effective anti CD154 antibodies for therapeutic intervention

    SBC: Immunext, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant In both animal proof of concept studies and preliminary clinical trials there is ample data demonstrating the potential therapeutic benefits o CD blockade for treatment of GVHD organ transplantation and autoimmune diseases However development of CD as a therapeutic has been impeded by antibody toxicity observed in early clinical trials GVHD is a ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Safe And Effective Anti-CD154 Antibodies For Therapeutic Intervention

    SBC: Immunext, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): There is compelling evidence that ?CD154 treatment has great potential in autoimmunity and graft rejection. Autoimmunity. Clinical efficacy of ?CD154 treatment has been seen in Lupus and idiopathic thrombocytopenia. In addition, Principal Investigator Dr. Noelle's clinical experience with ?CD154 is based on a Phase I trial in remitting/ relapsi ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Combination immunotherapies for the treatment of melanoma

    SBC: CELDARA MEDICAL, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Melanoma is the most common form of cancer in young adults1, and its incidence is rising at a rate higher than any of the seven most common cancers2, increasing 45% between 1992 and 20043. Plexxikon and Roche are codeveloping a BrafV600E inhibitor (i.e. PLX4032 (Vemurafenib)) and BMS/Medarex recently attained FDA approval for their anti-CTLA4 antibody (i.e. ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Wireless and Noise Attenuating Headset for Automated Hearing Screening

    SBC: CREARE LLC            Topic: NIDCD

    DESCRIPTION (provided by applicant): Hearing loss is a leading public health concern, with about 17% of American adults reporting some degree of impairment. Of those, fewer than 20% seek help for their condition for a variety of reasons. To address this issue, the National Institue of Deafness and Other Communication Disorders (NIDCD) is seeking solutions to improve hearing healthcare access and l ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. An Automated Platform for High-throughput Network Electrophysiology

    SBC: Calista Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Developing an Improved Electrocompetent E. coli Host

    SBC: Pro-Change Behavior Systems Inc            Topic: NCATS

    DESCRIPTION (provided by applicant): Chronic musculoskeletal pain creates a significant public health burden. Veterans are disproportionately affected by chronic musculoskeletal pain, and in particular, chronic low back pain (CLBP). The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), and all three conditions (Post-deployment Multi-symptom Disorder (PM ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Chloroquine Sensitive Plasmodium falciparum for MultiValent Vaccine and Challenge

    SBC: Simbex LLC            Topic: NINR

    DESCRIPTION (provided by applicant): The Principal Objective of this Fast Track SBIR project is to develop and validate a cost-effective commercial product, TheraSense , a highly innovative active support surface bed system for the treatment and prevention of serious decubitus ulcers, commonly known as bed sores or pressure ulcers. Current advanced bed systems for both institutional and home ther ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Adherence Monitoring for Substance Abuse Clinical Trials

    SBC: CREARE LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): The evaluation and selection of safe and effective pharmacotherapies for drug abuse and addiction, as well as many other diseases and disorders, is performed through clinical trials that rely on patients taking the studied medication at the specified time and frequency. To ensure accurate efficacy measures, adherence to the prescribed regimen must be known. Cr ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government